Guideline-Based Statin Eligibility, Coronary Artery Stenosis and Cardiovascular Events in Patients with Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial by Amit Pursnani, Jana Taron, Thomas Mayrhofer, Michael T. Lu, Maros Ferencik, Joseph A. Ladapo, Pamela S. Douglas, Udo Hoffmann

“…Background: Recommendations for preventive statin treatment in patients with stable chest pain may be difficult as symptoms can be unspecific. …”
Get full text

Lipoprotein Subclasses Associated With High‐Risk Coronary Atherosclerotic Plaque: Insights From the PROMISE Clinical Trial by Robert W. McGarrah, Maros Ferencik, Stephanie N. Giamberardino, Udo Hoffmann, Borek Foldyna, Julia Karady, Geoffrey S. Ginsburg, William E. Kraus, Pamela S. Douglas, Svati H. Shah

“…These findings may aid in the risk stratification of individuals with chest pain and provide insight into the pathobiology of HRP. …”
Get full text

Branched‐Chain Amino Acids in Computed Tomography–Defined Adipose Depots and Coronary Artery Disease: A PROMISE Trial Biomarker Substudy by Elizabeth Zhao, Stephanie N. Giamberardino, Neha J. Pagidipati, Deepak Voora, Geoffrey S. Ginsburg, Udo Hoffmann, Júlia Karády, Maros Ferencik, Pamela S. Douglas, Borek Foldyna, Svati H. Shah

“…Methods and Results The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial randomized 10 003 outpatients with stable chest pain to computed tomography angiography versus standard‐of‐care diagnostics. …”
Get full text

Plasma Lipidomic Patterns in Patients with Symptomatic Coronary Microvascular Dysfunction by Jonathan R. Lindner, Brian P. Davidson, Zifeng Song, Claudia S. Maier, Jessica Minnier, Jan Frederick Stevens, Maros Ferencik, Sahar Taqui, J. Todd Belcik, Federico Moccetti, Michael Layoun, Paul Spellman, Mitchell S. Turker, Hagai Tavori, Sergio Fazio, Jacob Raber, Gerd Bobe

“…Subjects (<i>n</i> = 20) aged 35–60 years and referred for computed tomography coronary angiography (CTA) for chest pain but who lacked obstructive CAD (>50% stenosis), underwent quantitative regadenoson stress-rest myocardial contrast echocardiography (MCE) perfusion imaging for MVD assessment. …”
Get full text

Risk factors for cardiovascular disease among individuals with hepatic steatosis by Julia Karády, Maros Ferencik, Thomas Mayrhofer, Nandini M. Meyersohn, Daniel O. Bittner, Pedro V. Staziaki, Balint Szilveszter, Travis R. Hallett, Michael T. Lu, Stefan B. Puchner, Tracey G. Simon, Borek Foldyna, Geoffrey S. Ginsburg, Robert W. McGarrah, Deepak Voora, Svati H. Shah, Pamela S. Douglas, Udo Hoffmann, Kathleen E. Corey

“…We performed a nested cohort study of adults with HS detected on coronary computed tomography in the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial. Obstructive CAD was defined as ≥50% coronary stenosis. …”
Get full text